Blog Post

Blog Post

Clinical Trial Alert: Phase 3 Study of Rozanolixizumab in Individuals With Generalized Myasthenia Gravis

By MDA Staff | February 23, 2021
Blog Post

MDA Welcomes Dr. Don Wood as its New President and CEO

By Nancy Intrator | February 16, 2021
Blog Post

How Expedited Drug Approval Impacts the Neuromuscular Disease Treatment Landscape

By Sujatha Gurunathan | February 4, 2021
Blog Post

MDA’s 2021 Advocacy Plan

By Mark Fisher | February 2, 2021
Blog Post

MDA Let’s Play Community Spotlight: NegaGrier

By Jeff Shaw | January 29, 2021
Blog Post

Research Study Alert: Survey on the Mental Health Experience of Parents and Guardians of Children With DMD

By MDA Staff | January 27, 2021
Blog Post

Research Study Alert: LGMD2I Natural History Study

By MDA Staff | January 25, 2021
Paige Lembeck, PhD
Blog Post

Meditation and Neuromuscular Disease

By MDA Staff | January 7, 2021
Blog Post

MDA Advocacy’s 2020 Year in Review

By Mark Fisher | December 18, 2020
Blog Post

What You Need to Know About Open Enrollment in 2020

By Mark Fisher | November 20, 2020